CURRICULUM VITAE’ (Updated March 29, 2015)
`
`Jeffrey Fudin, R.Ph., B.S., Pharm.D., DAAPM, FCCP, FASHP
`
`
`
`
`
`
`Web Addresses:
`www.paindr.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Address:
`
`
`Dr. Jeffrey Fudin
`
`REMITIGATE, LLC
`PO Box 214
`
`Delmar, NY 12054-0214
`
`
`
`
`
`781-4-PAINDR (Professional)
`518-772-4100 (Fax)
`
`e-mails: jeff@paindr.com (professional, preferred)
`Jeffrey.fudin@uconn.edu
`Twitter: @JeffreyFudin
`
`
`
`
`
`
`
`VAMC Office, (Gov’t Related Business Only, per request)
`VAMC Fax, (Gov’t Related Business Only, per request)
`
`
`
`EDUCATION:
`
` DEGREES:
`
`Albany College of Pharmacy (Union University): Pharm.D. Completed May 1998
`Albany College of Pharmacy (Union University): B.S. Pharmacy completed May 1981
`
`
`
`Pharm.D. Rotations:
`
`
`06/16/97-07/25/97: Counsel Administration with the New York State Counsel of Health-
`system Pharmacists
` New Karner Road Albany, NY
` Preceptor: Mary Andritz, Pharm.D.
`
`07/28/97-08/29/97: Anesthesiology/Pain Management at Albany Medical Center
`Hospital, AMCH Pain
` Clinic (Hackett Blvd, Albany), and VAMC (Holland Ave, Albany)
` Preceptor: Howard S. Smith, M.D.
`
`01/05/98-02/06/98: Ambulatory Care, The Endocrine Group
` 4 Executive Park Drive
` Albany, NY 12203
` Preceptor: Michael Kane, Pharm.D.
`
`02/09/98-03/13/98: HIV / Pharmacotherapy
` Albany Medical Center Hospital
` New Scotland Ave.
` Albany, NY 12208
` Preceptor: Bonnie Purdy, Pharm.D.
`
`CFAD VI 1028-0001
`
`

`

`
`03/23/98-04/24/98: Clinical Pharmacy
` St. Peter’s Hospital
` New Scotland Ave.
` Albany, NY 12208
` Preceptor: Lynn Hamil, Pharm.D.
`
`04/27/98-05/29/98: Cardiology
` Albany Medical Center Hospital
` New Scotland Ave.
` Albany, NY 12208
` Preceptor: Laura Bartels, Pharm.D.
`
`
`
`Veterans Administration Medical Center: Course: Management Assessment Training Program,
`completed 1987.
`
`Clinical Oncology Pharmacy Fellowship. Upstate Medical Center, SUNY, Syracuse, New York.
`Activities Included: Admixture of chemotherapeutic medications, monitoring blood parameters
`of oncology and hematology patients and recommending necessary adjustments to the attending
`oncologist. Lectured to pharmacists, medical students, oncology fellows, nurses, and physicians.
`Participated in clinical research with cancer drugs. Participated in daily rounds and monitored
`drug therapy for those patients who were referred to oncology service. Completed October 1981
`
`
`
`
`
`AWARDS
`
`
`2015: Named a Fellow to the American Society of Health-system Pharmacists.
`
`2015: March 2015 The Pain Community Hero. http://paincommunity.org/
`
`2014: American Academy of Pain Medicine’s (AAPM) Presidential Commendation, in
`recognition as “a voice for scientific integrity and an advocate for people in pain.” Presented
`March 8, 2014 at the AAPM Annual Meeting in Phoenix AZ.
`
`
`(Internal VAMC Awards since 1982, too numerous to list; available upon request only)
`
`2011: Cambridge Who’s Who Among Executives and Professionals.
`
`2010: Cambridge Who’s Who Among Executives and Professionals.
`
`2010: Elected Finalist in the “Lifetime Achievement “category of the Next-Generation Pharmacist
`Awards.
`
`
`2010: Inducted a Fellow to the American College of Clinical Pharmacy.
`
`2009: Who's Who Among Executives and Professionals, 2008-2009 "Honors Edition".
`
`2008: Who's Who Among Executives and Professionals, 2008-2009 "Honors Edition".
`
`2007: Who’s Who in Medicine and Healthcare
`
`
`
`2
`
`CFAD VI 1028-0002
`
`

`

`
`2006: Who’s Who in Medicine and Healthcare
`
`2006: International Health Professional of the Year. Nominated by the Research and Advisory
`Board at the International Biographical Centre in Cambridge, England.
`
`
`2006: Honors Edition of The United Who’s Who Registry.
`
`
`2005: The Outstanding Service to the Profession of Pharmacy Award honoring an alumnus or
`alumna who has made an exceptional contribution to the profession.
`
`
`June 16, 2003: NYS Assembly Bill #K1117 ADOPTED: “Honoring Dr. Jeffrey Fudin upon the
`occasion of his selection as Grand Marshal of the Albany Memorial Day Parade in Albany, NY.
`WHEREAS, Individuals who give of their time and energies and serve the best interests of their
`communities are an asset beyond remuneration and cannot be sufficiently extolled; and
`WHEREAS, Dr. Jeffrey Fudin has given not only of his time and energies but also of his
`competence, intelligence and leadership and consequently has been designated for special honor;
`and WHEREAS, This Assembled Body is justly proud to honor Dr. Jeffrey Fudin upon the
`occasion of his selection as Grand Marshal of the Albany Memorial Day Parade; and WHEREAS,
`Dr. Jeffrey Fudin was selected for this esteemed honor not only for his devoted work at the
`Stratton Veterans Administration Medical Center, but also for his dedication to the protection
`of patients at the VA…”
`
`2003: Appointed as Grand Marshal for the 5/26/03 Albany Memorial Day Parade by the City of
`Albany Joint Veterans Committee, for display of bravery in defending rights of veteran
`patients.
`
` 2003: Certificate of Commendation presented for serving as faculty at the Dept. of Veterans
`Affairs 3rd National Leadership Conference on Pain Management and End of Life Care.
`
` 2001: Certificate of Appreciation for Professional Commitment and Expertise, and for
`Partaking in Educational Efforts to Provide High-Quality Care through Better Pain
`Management to the Veterans Served by the VA New York Harbor Healthcare System.
`Presented at the New York Campus, VA NYHHS June 27, 2001.
`
`
`
`
`
`
` 2001: Certificate of Commendation presented for serving as faculty at the Dept. of Veterans
`Affairs 2nd National Leadership Conference on Pain Management and End of Life Care.
`
`
` 1997: Phi Delta Chi, Distinguished Pharmacist Alumni of the Year
`
` 1996: Unrestricted Research Grant, Dilaudid Stability and Cost Effectiveness.
` Granted by Knoll Pharmaceuticals
`
`
`1992: Who’s Who Among Rising Young Americans
`
`1991: Who’s Who Among Rising Young Americans
`
`
`
`
`
`
`1990: Who’s Who Among Rising Young Americans
`
`3
`
`CFAD VI 1028-0003
`
`

`

`1989: MSD Award for Superior Achievement in Pharmacy Practice
`
`1986: Syntex Pharmacist Preceptor of the Year Award
`
`1981: Smith, Kline and French Award for Superior Achievement in Clinical Pharmacy
`
`1981: Clinical Oncology Pharmacy Fellowship awarded by the American Cancer Society
`through Upstate Medical Center
`
`
`
`
`
`
`
`•
`•
`•
`•
`•
`
`
`
`EXPERIENCE
`
`07/1982 – present: Samuel Stratton Dept. of Veterans Affairs Medical Center
`113 Holland Avenue Albany, New York 12208
`
`4/2012-present: Director, PGY2 Pharmacy Pain Residency
`6/1994-present: Clinical Pharmacy Specialist, Pain Management
`7/2002-10/2003: Clinical Pharmacy Specialist, Primary Care & Pain Mgmt
`3/1987-6/1994: Clinical Pharmacy Specialist, Research/Oncology/Hematology
`7/1982-3/1987: Staff Pharmacist
`
`
`
`Current Activities Focus: The Clinical Pharmacy Specialist (CPS) works in close collaboration
`with medical staff members in the management of various acute and chronic pain disease states.
`After a diagnosis/diagnoses has/have been made and is/are documented in the electronic medical
`record, a specific request may be made by a physician or mid-level for the CPS to monitor a
`disease state(s) or assess a medication regimen and adjust, initiate, or discontinue
`therapy for individual patients. The CPS may also order and interpret lab tests necessary to
`monitor and support drug therapy upon such a request.
`
`Specific Patient Care Activities Include:
`
`
`• Conduct comprehensive appraisals of patients’ health status by taking health and drug
`histories. Relevant findings must be documented in the patient's medical record.
`• Evaluate drug therapy through direct patient care involvement, with clinical assessment
`and objective findings relating to patient's responses to drug therapy and communicating
`and documenting those findings and recommendations to appropriate individuals and in
`appropriate records (i.e., patient's medical record).
`• Develop and document therapeutic plans utilizing the most effective, least toxic, and
`most economical medication treatments.
`• Provide patient and health care professional education.
`• Order, perform, review, and analyze appropriate laboratory tests and other diagnostic
`studies necessary to monitor and support the patient's drug therapy.
` Prescribe medications, devices, and supplies to include, but not limited to: initiation,
`continuation, discontinuation, monitoring and altering therapy, based upon established
`protocols.
`• Perform the physical measurements necessary to ensure the patients appropriate clinical
`responses to drug therapy.
`• Assist in the management of medical emergencies, adverse drug reactions, and acute and
`chronic disease states.
`
`•
`
`
`
`4
`
`CFAD VI 1028-0004
`
`

`

`•
`
`Identify and take specific corrective action for drug-induced problems. Order consults
`(i.e., Anesthesia interventionalists, imaging, dietician, social work, psychology), as
`appropriate, to maximize positive drug therapy outcomes.
`
`
`Activities have previously and/or currently include:
`
`
`•
`
`•
`
`• Development of PGY2 Pharmacy Pain Residency
`• Develop and incorporate telemedicine options for remote VA patients
`• Monthly inservices to primary care providers on various pain topics.
`• Pharmacokinetic screening and serum analysis of opioid therapy
`• Development and implementation of Stratton VA Pain Clinic
`• Ambulatory Care Chronic Pain Clinic
`• Participate in daily pain management inpatient rounds to monitor and review pain
`management regimens on those patients referred to our service for chronic or acute pain
`management and/or PCA
`• Pain Management Multidisciplinary Team Member
`• Pain Management Multidisciplinary Team Chair
`• Director, Pharmaceutical Care Pain Clinic
`• Write Drug Utilization Review (DUR) and guidelines
`• Coordinate and ran weekly Pharmaceutical Care Neurosurgery Pain Management Clinic.
`Activities
`Include patient evaluation, counseling, physical assessment, prescription writing and
`patient follow-up.
`• Design, conduct and participate in drug studies, audits and evaluations concerning the
`utilization review of analgesic and antineoplastic drugs under the auspices of Therapeutic
`Agents and Pharmacy Review Committee, Quality Assurance and Research and
`Development Committee.
`Instrumental in the development of a Multidisciplinary Pain Management Team. This
`included development of policies and procedures in conjunction with other health
`professionals, patient rounds, pain evaluation, and the management of pain with a
`multidisciplinary team. In addition, all referrals for Patient Controlled Analgesic (PCA)
`ambulatory infusion pumps had been coordinated, monitored, and followed up by the
`Oncology Pharmacist.
`• Member of the VAMC VISN Eastern Regional Pain Task Force.
`Initiated, developed, and supervised the Oncology Satellite. This included establishing a
`•
`multidisciplinary team and writing initial policies for safe handling of cytotoxic drugs
`within the VA Hospital. We were the first hospital in the northeastern New York State to
`establish such policies, and our policies were used as a model for pharmacies throughout
`New York State.
`• Evaluate drug literature by analysis of experimental design and conclusions, in order to
`compare and contrast therapeutic regimens and uses for new drug therapies.
`• Designed antineoplastic drug dosage regimens utilizing pharmacokinetic principles and
`specific patient parameters, when requested by the attending physician.
`• Provided drug information to various health care providers on all investigational drugs
`being utilized in the Medical Center and ensured availability of current drug information
`in Pharmacy, Medical and Nursing Services. Responsibilities included meeting with
`various investigative sponsors, writing and editing protocols, educating pharmacy,
`nursing and medical staff, and procuring, preparing, and dispensing medication.
`
`
`
`5
`
`CFAD VI 1028-0005
`
`

`

`
`
`• Prepared bulletins, newsletters and policy memos to inform physicians, nurses,
`pharmacists and other staff on the appropriate utilization of medications.
`• Served as a consultant to the Therapeutic Agents and Pharmacy Reviews Committee on
`the selection of antineoplastic drugs for formulary listing.
`• Attended Tumor Board meetings on a regular basis and aided in the selection of
`appropriate antineoplastic drug therapy.
`• Developed and co-coordinated the high tech Homecare department at the V.A.
`• Coordinated Pharmacy Grand Rounds, educational seminars for pharmacy, medical, and
`nursing staff.
`
`Committees Have or Currently Include:
`
`• Cancer Committee
`• Chairman, Pain Oversight Committee – VAMC, Albany
`• Education Subcommittee (Implementing Pain as “The Fifth Vital Sign”)
`• Ethics Committee
`Integrated Ethics Committee
`•
`• Human Studies Committee (voting member and non-voting member)
`Infectious Disease Journal Club
`•
`• National VA Pain Committee
`• National VA Pain Research Committee
`• National VA Pain Website Development Committee
`• National VA Institute for Health Care Improvement (IHI) Pain Task Force
`• National VA Pharmacy Pain Education Committee
`• Palliative Care Committee
`• Pharmacy and Therapeutics Committee
`• Pressure Ulcer Committee
`• Research and Development (voting member and non-voting member)
`• Stratton VAMC Integrated Ethics Committee
`• Surgical PCA Task Force
`• Tumor Board
`• VISN NE United States Pain Committee – VAMC, Albany
`
`
`Primary Care Responsibilities:
`
`• Medication Monitoring
`• Polypharmacy
`• Adverse drug reactions
`• Drug interactions
`• Medication compliance
`• Laboratory monitoring for patients newly placed on antilipemic agents and dose titration
`as necessary.
`• Frequent vital sign and laboratory monitoring for patients newly placed on
`antihypertensive agents and dose titration as necessary.
`• Diabetic or asthmatic patients needing follow-up after a medication regimen change.
`• Patient follow-up after recent formulary agent change to a nonformulary agent.
`
`6
`
`
`
`
`
`
`
`
`
`CFAD VI 1028-0006
`
`

`

`•
`
`Interim therapeutic drug monitoring for agents such as phenytoin, carbamazepine,
`digoxin, theophylline, etc.
`• Patients recently initiated on warfarin in need of extensive education.
`
`
`04/2002-6/2002: Regional Medical Liaison for Amgen – Upstate New York Area (subcontract through
`BestMed, a subsidiary of Saachi and Saachi)
`
`
`02/1989 – 10/1989:
`Director Clinical Pharmacy Affairs
`O.P.T.I.O.N. Care
`
`O.P.T.I.O.N. Care
`57 Phila Street
`
`58 Hackett Boulevard
`Saratoga, N.Y. 12866
`
`Albany, N.Y. 12208
`
`
`
`
`
`
`
`
`
`Activities Include:
`• Planning, setting up, and registering 2 pharmacies at locations listed above. Pharmacies
`to include clean rooms and all appropriate and equipment as required by New York State
`and Federal law.
`
`• Extensive 2 week course in I.V. admixture, home health care design, billing, clinical
`pharmacy in the home care setting, review of ambulatory pumps, review of drug
`therapies in the home setting including central and peripheral lines, etc. This course took
`place at O.P.T.I.O.N. Care corporate office in Chico, California.
`
`• As an owner, all requirements for development of a Professional corporation had to be
`met as well as those tax and other legal requirements to commence a professional
`business in New York State.
`
`• Professional activities included marketing, joint visits to physician clinics with patients.
`House calls to patients’ homes, parenteral drug administration to patients, programming
`pumps, admixing medication, inventory control.
`
`
`
`11/1981-07/1982: Staff Pharmacist, The Cornwall Hospital, Cornwall, New York.
`
`
`ACADEMIC AFFILIATIONS & TEACHING ACTIVITIES
`
`October 1998-present: Adjunct Associate Professor of Pharmacy Practice, Albany College of Pharmacy
`& Health Sciences/Union University in Albany NY.
`Initiated new elective course in Pain Management Therapeutics (1/2012), Pain Management
`•
`Pharmacotherapy PHM 551.
`
`
`April 2014-present: Adjunct Associate Professor, Western New England University College of
`Pharmacy
`
`July 2013-present: Adjunct Assistant Professor of Pharmacy Practice, University of Connecticut School
`of Pharmacy in Storrs CT.
`Instructor for elective course in Pain Management, Advanced Clinical Concepts in Pain
`•
`Management PHRX 4055.
`
`
`
`7
`
`CFAD VI 1028-0007
`
`

`

`
`2008 – present: Adjunct Advanced Practice Clinical Instructor for Advanced Pharmacy Practice, State
`University of New York College of Pharmacy at Buffalo NY.
`
`2008 – 2010: Adjunct Advanced Practice Clinical Instructor for Advanced Pharmacy Practice, St. John
`Fisher College of Pharmacy at Rochester NY.
`
`January 1997-present: Adjunct Instructor for Advanced Pharmacology (NSG 622), SAGE Graduate
`School of Nursing, Nurse Practitioner Program. Albany, NY
`
`June 1997-2005: Adjunct Instructor for Psychopharmacology (NSG 624), SAGE Graduate School of
`Nursing, Nurse Practitioner Program. Albany, NY
`
`January 2000-2004: Adjunct Instructor for Pharmacotherapeutics. SAGE Graduate School of Physical
`Therapy
`
`October 2003-August 2004: Preceptor, Albany Medical College. Evidence Based Health Care,
`SURGERY. Instructor, Palliative Care Medical Fellowship
`
`January 1999-July 2000:
`Anesthesiology Medical Fellowship Committee, Albany Medical College. Albany, NY
`
`January 1998-2001:
`Hudson Valley Community College (Physician Assistant Program w/ Albany Medical College)
`Instructor for Geriatric Pharmacology. Albany, NY
`
`
`PROFESSIONAL ASSOCIATIONS (past and present)
`
`
`• American Pain Society
`• Pharmacists Society of the State of New York (PSSNY)
`• NYS Chapter of American College of Clinical Pharmacy, since 3/2000
`• American College of Clinical Pharmacy, since 7/98
`o Pain Practice Research Network Group (Chairman), ACCP, 9/1998-11/1999, 11/2003-
`10/2004)
`o Pain Practice Research Network Group (Sec-Treas), ACCP, 11/99-11/2003
`• American Society of Health-system Pharmacists, since 1978
`• Northeastern NYS Council of Health-system Pharmacists(Public and Legal Affairs
`Representative for Northeastern Chapter, since 1982- 1992)
`• American Academy of Pain Management
`• Phi Delta Chi Pharmaceutical Fraternity (Faculty Advisor May 1987 - Present)
`• American Cancer Society, Northeastern Chapter
`• American Hospice Association
`• The New York Academy of Sciences
`International Society of Chronobiology
`•
`
`
`
`PROFESSIONAL LICENSURE AND BOARD CERTIFICATION
`
`
`
`8
`
`CFAD VI 1028-0008
`
`

`

`• Registered Pharmacist in New York State (License 34085)
`• Board Certified as a Diplomat to the American Academy of Pain Management
`• Diplomate to the American Academy of Pain Management
`• American Heart Association BLS for Healthcare Providers (CPR and AED), certified
`through 9/2015.
`
`
`
`SCHOLARLY ACTIVITY
`
`
`
`
`
`
` •
`
` PUBLICATIONS
`
`
`
`
`
`Peer Reviewed Journals (Pharmacy, Medical, Scientific, Nursing, Other)
`
`Ahmed N, Horlacher RJ, Pham T, Fudin J. Adrenergic agonists and
`sympatholytic agents in the prevention or treatment of opioid withdrawal.
`Practical Pain Management. 2015 May; 15(5): In press.
`
`Fudin J, Kominek C. Naloxegol Descheduled. Practical Pain Management.
`2015 March 15(2):17.
`
`Tennant F, Guess S, Gudin J, Fudin J. Rationale for Medical Management.
`Practical Pain Management. 2015 Jan-Feb; 15(1):36-44.
`
`Linares OA, Daly D, Fudin J, Daly-Linares A, Stefanovski D, Boston RC.
`Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics,
`and Pharmacokinetic Dosing. The Clinical Journal of Pain. In Print.
`
`Linares OA, Fudin J, Schiesser WE, Daly-Linares AL, Boston RC. CYP2D6
`Phenotype-Specific Codeine Population Pharmacokinetics.
`Journal of Pain & Palliative Care Pharmacotherapy. 2015;Early Online:1–12.
`
`Fudin J. Hydrocodone Metabolism. Letter to the Editor. Practical Pain
`Management. 2014 Nov/Dec; 14(10): 12-14.
`
`Gudin J, Laitman A, Fudin J, Kominek C. Combating Opioid-induced
`Constipation:New and Emerging Therapies. Practical Pain Management. 2014
`Nov/Dec; 14(10):41-48.
`
`Atkinson TJ, Fudin J, Wegrzyn E, Bettinger, J. Dialysis, Opioids, and Pain
`Management: Where’s the Evidence? Practical Pain Management. 2014
`September; 14(8): 49-57.
`
`Atkinson TJ, Fudin J. Interactions Between Pain Medications And Illicit Street
`Drugs. Practical Pain Management. 2014 August; 14(7): 50-61.
`
`Twillman R, Fudin J. Potential Cost-Shifting And Hidden Costs And Risks In
`The Economic Analysis Of Opioid Abuse Deterrent Formulations. Pain
`Medicine. 2014; 15: 1447–1449.
`
`Linares OA, Fudin J, Schiesser WE, Linares AD, Boston RC. Oxycodone
`
`9
`
`CFAD VI 1028-0009
`
`

`

`Recycling: A Novel Hypothesis of Opioid Tolerance Development in Humans
`Medical Hypotheses. 2014;326–331.
`
`Meghani SH, Kang Y, Chittams J, Mao JJ, McMenamin E, Hanlon A, Fudin J.
`African Americans with Cancer Pain Are More Likely to Receive an Analgesic
`with Toxic Metabolite Despite Clinical Risks: A Mediation Analysis Study. J
`Clin Oncol. 2014 Sep 1;32(25):2773-9.
`
`Atkinson TJ, Schatman ME, Fudin J. The Damage Done By the War on
`Opioids: The Pendulum Has Swung Too Far. Journal of Pain Research. May
`2014. 265-268.
`
`Fudin J, Atkinson TJ. Personalized Oxycodone Dosing: Using Pharmacogenetic
`Testing and Clinical Pharmacokinetics to Reduce Toxicity Risk and Increase
`Effectiveness. Editorial. Pain Medicine. Volume 15, Issue 5, pages 723–725,
`May 2014.
`
`Fudin J, Atkinson TJ. Opioid Prescribing Level Off, but is Less Really More?
`Pain Medicine. January 2014. 2014; 15: 184–187.
`
`Fudin J. The hydrocodone question [In My View]. Drug Topics. 2013 Dec. Vol.
`157, No.12, Pages 14-16. (Also available online at
`http://drugtopics.modernmedicine.com/drug-topics/news/hydrocodone-question)
`
`Atkinson TJ, Fudin J, Jahn HL, Kubotera N, Rennick AL, Rhorer M. What’s
`New in NSAID Pharmacotherapy? Pain Medicine. NSAID Supplement. Volume
`14, Issue Supplement S1, pages S11–S17, December 2013.
`
`Younan M, Atkinson TJ, Fudin J. A Practical Approach to Discontinuing
`NSAID Therapy Prior to a Procedure. Practical Pain Management. 2013
`Nov/Dec; 13(10):45-51.
`
`Atkinson TJ, Fudin J, Pandula A, Mirza M. Medication Management in the
`Elderly: Unique and Underutilized Treatment options. Clinical Therapeutics.
`2013 Nov. Vol. 34, Pages 1669-1689.
`
`Dole E, Fudin J. Pharmacists speak out: The AMA’s “drug store intrusion”
`resolution and Walgreens’ “good faith dispensing” policy. Drug Topics. 2013
`Oct. Vol. 157, No.10, Pages 9-10.
`
`Fudin J, Fontenelle DV, Fudin HR, Carlyn C, Ashley CC, Hinden DA. Potential
`P-glycoprotein Pharmacokinetic Interaction of Telaprevir with Morphine or
`Methadone. Journal of Pain and Palliative Care Pharmacotherapy. August 2013,
`Vol. 27, No. 3, Pages 261-267.
`
`Shaw K, Fudin J. Evaluation and Comparison of Online Equianalgesic Opioid
`Dose Conversion Calculators. Practical Pain Management. 2013 August;
`13(7):61-66.
`
`Donovan KJ, Fudin J. How Changing Hydrocodone Scheduling Will Affect Pain
`10
`
`
`
`CFAD VI 1028-0010
`
`

`

`Management. Practical Pain Management. 2013 June; 13(5):69-74.
`
`Sasu-Tenkoramaa J, Fudin J. Drug Interactions in Cancer Patients Requiring
`Concomitant Chemotherapy and Analgesics. Practical Pain Management. 2013
`May: 13(4):50-64.
`
`Sasu-Tenkoramaa J, Fudin J. Neuropathy in the Cancer Patient: Causes and
`Cures. Practical Pain Management. 2013 April; 13(3):53-67.
`
`Kubotera N, Fudin J. Pain Management for Pharmacists – Concepts and
`Definitions. CE program of the University of Connecticut School of Pharmacy
`and Drug Topics. Drug topics. 2013 April:52-61.
`
`Fudin J, Fontenelle DV, Payne A. Rifampin Reduces Oral Morphine
`Absorption; A Case of Transdermal Buprenorphine Selection Based on Morphine
`Pharmacokinetics. Journal of Pain & Palliative Care Pharmacotherapy.
`2012;26:362–367.
`
`Fudin J. Commentary. PROMPT Challenges PROP’s Petition. October 2012.
`12-14. Practical Pain Management. 2012 October; 12(9):12-14.
`
`Fudin J, Marcoux MD, Fudin JA. Mathematical Model For Methadone
`Conversion Examined. Practical Pain Management. 2012 September; 12(8): 46-
`51.
`
`Brennan MJ, Fudin J, Perkins RJ. Opioid Calculator Online. Practical Pain
`Management (incorporating the “Methadone Fudin Factor”). January 2012.
`http://opioidcalculator.practicalpainmanagement.com/.
`
`Crana S, Fudin J. Drug Interactions Among HIV Patients Receiving Concurrent
`Antiretroviral and Pain Therapy. Practical Pain Management 2011 October;105-
`118,120-124.
`
`Fudin J. Update on Risk Evaluation and Mitigation Strategies (REMS)
`associated with long-acting opioids. . CE program of the University of
`Connecticut School of Pharmacy and Drug Topics. Drug topics. 2011
`October:45-58.
`
`Fudin J. Opioid pain management: Balancing risks and benefits. CE program of
`the University of Connecticut School of Pharmacy and Drug Topics. Drug topics.
`2011 September:46-58.
`
`Zorn KE, Fudin J. Treatment of neuropathic pain: the role of unique opioid
`agents. Practical Pain Management. 2011 May; 11 (4): 26-33.
`
`Nerenberg DM, Fudin J. Letter to the editor in AJHP. Maximum daily dose of
`hydrocodone. Am J Health-Syst Pharm—Vol 67 Oct 1, 2010. 1588.
`
`McCarberb B, Pasik SD, Fudin J. Chronic Pain Management: Overcoming
`Barriers to Treatment (Part 1 in a 3-Part Series). An online C.E program by the
`11
`
`
`
`CFAD VI 1028-0011
`
`

`

`Medical learning institute. https://www.mlicme.com/mlicme/. June 28, 1010.
`
`Marcucci C, Fudin J, Thomas P, et al. A new pattern of buprenorphine misuse
`may complicate perioperative pain control. [Case Reports, Letter]. Anesth Analg
`2009 Jun; 108(6):1996-7.
`
`Tristani L, Fudin J. Rational Polypharmacy and Pain Medications in the Elderly.
`Pain.com. March 2, 2009.
`(http://www.pain.com/sections/professional/articles/article.cfm?id=104, last
`accessed 02-25-2010).
`
`McCarberg B, Bainbridge JL, Fudin J. Optimizing chronic pain management:
`integrating pharmacokinetics and pharmacodynamics. Clinical Courier. 2009
`Jun; 27 (3): 1-8.
`
`Chou R,1 Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P,6 Donovan
`MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A,
`O’Connor PG,Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG,
`Todd KH, Miaskowski C. FOR THE AMERICAN PAIN SOCIETY–
`AMERICAN ACADEMY OF PAIN MEDICINE OPIOIDS GUIDELINES
`PANEL Opioid Treatment Guidelines, Clinical Guidelines for the Use of Chronic
`Opioid Therapy in Chronic Noncancer Pain. The Journal of Pain, Vol 10, No 2
`(February), 2009: pp 113-130.
`
`Medscape Pharmacist, As listed on “Ask the Expert”
`
`
`What Should Patients Do With Unused Narcotics? Response from
`Jeffrey Fudin, PharmD. Experts And Viewpoints, Medscape
`Pharmacists, November 2009.
`
`What Is the Maximum Safe Dose of Opioids? Response From the Expert
`Jeffrey Fudin, BS, PharmD. Experts And Viewpoint, Medscape
`Pharmacists, February 2008.
`
`Why Avoid Administering Preservative-Containing Drugs Into the
`Central Nervous System? Response from Jeffrey Fudin, BS, PharmD.
`Experts And Viewpoint, Medscape Pharmacists, January 2009.
`
`Does Calcitonin Help Relieve Neuropathic Pain? Response from Jeffrey
`Fudin, BS, PharmD. Experts And Viewpoint, Medscape Pharmacists,
`January 2009.
`
`What's the Best Pain Management Strategy for Neonates? Response
`From the Expert Jeffrey Fudin, BS, PharmD. Medscape Pharmacists,
`October 2007.
`
`Can Fentanyl Patches Be Replaced Sooner to Improve Pain Control?
`Response From the Expert Jeffrey Fudin, BS, PharmD. Experts And
`Viewpoint, Medscape Pharmacists, January 2008.
`
`
`12
`
`
`
`
`
`
`
`CFAD VI 1028-0012
`
`

`

`Can Opiates Be Administered by Nebulizer? Response From the Expert
`Jeffrey Fudin, BS, PharmD. Experts And Viewpoint, Medscape
`Pharmacists, May 2008.
`
`Can Opioid Tolerance Be Treated by Increasing the Opioid Dose?
`Response from Jeffrey Fudin, PharmD. Medscape Pharmacists,
`September 2009.
`
`Optimizing Pain Control With Fentanyl Patches
`Meredith McLean, PharmD; Jeffrey Fudin, BS, PharmD. Experts And
`Viewpoint, Medscape Pharmacists, July 2008.
`
`Fudin J, McCarberg BH, Pasternak G, Schechter LN, Schnoll SH, Lande SD.
`Pharmacist perspective on extended release analgesics for persistent pain.
`Pharmacy Today. 13(10):54–68. October 2007.
`
`Raymo LL, Camejo M, Fudin J. Eradicating analgesic use of meperidine in a
`hospital. AJHP pp. 1150-1153. June 1, 2007. Am J Health-Syst Pharm—Vol 64
`Jun 1, 2007.
`
`Carson J, Black J, Czarkowski C, Fudin J, Nolan D, Springman M,
`Commentary: Lack of protection for whistleblowers imperils us all. Federal
`Times. April 16, 2007. (www.federaltimes.com/index.php?S=2681966, last
`accessed 04-16-2007).
`
`Fudin J. Blowing the Whistle: A Pharmacist’s Vexing Experience Unraveled.
`Am J Health-Syst, Pharm. 2006; 63:2262-5. (FEATURE ARTICLE OF THE
`WEEK, as posted by Medscape 01-2007)
`
`Fudin J. Blowing the whistle on veteran harm. Federal Practitioner. pp. 41-42.
`March 2006.
`
`Kral LA, Leavitt SB. (MR: Fudin J.) Opioid Tapering. Safely Discontinuing
`Opioid Analgesics. Pain Treatment Topix. pp.1-7, March 2006.
`
`Throm MJ, Fudin J, Otis. Managing Chronic Pain: An Analysis of the use of
`Opioids. Continuing Education Feature Article. Pharmacy Times. pp. 88-99,
`July 2005.
`
`Otis J, Fudin J. Use of Long-Acting Opioids for the Management of Chronic
`Pain. Continuing Education Feature Article. US Pharmacist. February 2005.
`
`Fudin J, Levasseur DJ, Passik SD, Kirsh KL, Coleman J. Chronic pain
`management with opioids in patients with past or current substance abuse
`problems. Journal of Pharmacy Practice. 2003, 16;4:291-308.
`
`Fudin J et. al. Department of Veterans Affairs National Pain Web Site: Opioids
`in the Management of Acute and Chronic Pain, located at
`http://208.34.95.200/painmanagement/
`
`
`
`
`
`
`
`
`
`13
`
`CFAD VI 1028-0013
`
`

`

`Turner M, Fudin J, Affonso A, Rivera W. Letter to the editor in American
`Journal of Hospice and Palliative Care. Vol. 18, No. 6, Nov-Dec. 2001.
`
`Clause S, Fudin J, Mergner A, Lutz JL, Kavanaugh MM, Fessler K,
`Chirumamilla S. Prescribing privileges among pharmacists in veterans affairs
`medical centers. Am J Health-syst Pharm. Vol.58, June 15, 2001, pp. 1143-1145.
`
`Fudin J, Aiken C. Pharmacotherapeutic considerations in chronic pain. Federal
`Practitioner. August 2001. Vol.18, No.8s, pp.10-17.
`
`Fudin J, Smith HS, Toledo-Binette CS, Kenny E, You ABC, Boutin R. Use of
`continuous ambulatory infusions of concentrated subcutaneous (SC)
`hydromorphone versus intravenous (IV) morphine: cost implications for
`palliative care. American Journal of Hospice and Palliative Care. volume 17,
`number 5, September/October 2000. pp. 347-353.
`
`Premo K, Kupiak D, Fudin J. Evaluation of compliance with prescribing
`guidelines for 5HT-3 inhibitors. The New York Health-system Pharmacist.
`September/October 2000. Volume 19 Number 5. Pg 23.
`
`Fudin J, Sue, Eunyoung Silvie. An Update on the Therapeutic Use of Opioids in
`Acute and Chronic Pain. Supportive Voice. Spring 2000. Vol.6 No.2. pp. 13-15.
`
`Fudin J, Audette C. Randomized Double blind Study Comparing the Efficacy of
`Gabapentin with Amitrityline on Diabetic neuropathy Pain. Letter to the Editor,
`Archives of Internal Medicine. Vol 160. April 10, 2000. pp.1040-1041.
`
`
`
`
`
`Fudin J, Allen JS. Nitrofurantoin Induced Neuropathy and Muscle Weakness: A
`Case Report with Chronic Use. Consultant Pharmacist. 15:1, Jan 2000. pp. 45-
`48.
`
`Fudin J, Kupiak D, Smith HS, Johnston KR, Binette CS. Therapy
`Consultation: Quicker Dosage adjustment for Transdermal Fentanyl. American
`Journal of Health-System Pharmacy, Vol. 54, Jan 1, 1997. pp.87-88.
`
`Smith H, Johnston KR, Fudin. Enteral Patient-controlled Analgesia, Letter to
`the Editor, The Lancet, vol. 344, October 15, 1994, p. 1092.
`
`
`Johnston KR, Fudin J, Administration of Bupreno